USFDA recognized Antrodia cinnamomea mycelia (NDIN No.1170)
Retrieved on:
Wednesday, May 19, 2021
The USFDA NDI acknowledgement without objection to Greenyn\'s Antromax was the 1st notification after numerous attempts in the past 14 years.
Key Points:
- The USFDA NDI acknowledgement without objection to Greenyn\'s Antromax was the 1st notification after numerous attempts in the past 14 years.
- We are honored to establish a stepping-stone for the A. cinnamomea to the US health markets estimated at 10 billion US dollars.\nDr.
- It was a great feat for Greenyn, and will certainly boost the morale of the Antrodia industry to devote more resources in the US market.\nA.
- It is foreseeable that the health benefits of A. cinnamomea to the world during covid-19 will create another pride for Taiwan.\n'